A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
OPEN TO ACCRUAL
III
NCT06592924
benedito.carneiro@BrownHealth.org
